Nanovi strengthens its Board of Directors and Management
24 January 2019
Nanovi A/S (Nanovi) has put in place new competences both on its Board of Directors and in the management team. The competence lift is a core element in Nanovi’s development from a research and development focused organization to a fully operational and commercial business.
Simon Hesse Hoffmann has been named as new Chairman of the Board. Simon Hesse Hoffmann was elected to Nanovi’s Board of Directors in May 2018, bringing experience that spans financial management, governance and reporting as well as budgeting and funding. He is Director of JHO Holding, has several board positions and previously held financial positions in publicly listed Danish companies. Simon holds a Master of Science in Finance and International Business.
Simon Hesse Hoffmann replaces Thomas L. Andresen, Professor at the Healthtech department of the Danish Technical University, DTU, and Nanovi founder. Thomas L. Andresen continues as ordinary board member.
Further, Ole Kring has been elected new member to represent the Danish Growth Foundation, Vækstfonden, which is Nanovi’s main shareholder. Ole Kring is Investment Director in Vækstfonden and brings +25 years of management, strategic and operational experience from the medical technology industry. He is founder of Scandinavian Micro Biodevices, where he was CEO for 12 years, including after the company was acquired by Zoetis Inc. in 2016. Ole has a background in management consultancy and holds a Master of Science in Economy & Business Administration.
Nanovi has also strengthened its management team.
As of January 1st, 2019, Sten Naae Hornsleth has taken up the position as Director of Sales & Marketing. Sten Naae Hornsleth brings considerable sales experience and a thorough understanding of the radiotherapy market, which is the target market for Nanovi’s first human product, BioXmark®, a soft tissue marker intended for use to enhance precision and enable better image-guided radiotherapy outcomes for cancer patients. Sten has +20 years of commercial experience, including +14 years as Managing Director of the Scandinavian subsidiary of Varian Medical Systems, a world leading supplier of specialized radiotherapy equipment. He holds a Master of Science and a PhD. in Electronic Engineering. In 2018,
Nanovi appointed another strong profile, Michael Wrang Mortensen, as Director of Supply and Development. Michael Wrang Mortensen brings +10 years of experience from the medical technology industry, including several years with Ferrosan Medical Devices A/S. He has held leadership positions in R&D teams as well as in development and operational projects in international organizations. Michael holds both a Master of Science in Engineering from the Danish Technical University and a PhD degree in Chemistry.
Jesper Boysen, CEO of Nanovi commented: “We are in the process of building full scale commercial operations, a significant step forward for Nanovi. In 2018, we had first sales of PetXmark™ for veterinary use in the US and in 2019, we expect to get BioXmark® CE marked for human use. At this decisive stage it is essential to have coherent management competences in place, including strong strategic, commercial and operational experiences. The profiles, we have attracted over the past year have strengthened our competence span, and I am confident we have set the scene right to successfully advance Nanovi into the next phase of development.”